Jun 30, 2020 7:00am EDT Can-Fite Announces Final Data Analysis from Phase II NASH Study: Highly Significant and Sustained Reduction in Liver Fat Volume Throughout Study Period
Jun 09, 2020 7:00am EDT Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S.
Jun 08, 2020 7:25am EDT Can-Fite Participating in BIO Digital International Convention and One-on-One Partnering Meetings on June 8-12, 2020
Jun 04, 2020 7:14am EDT Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver Cancer
Jun 03, 2020 7:00am EDT Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on June 4th
Jun 01, 2020 7:00am EDT Can-Fite Reports First Quarter 2020 Financial Results & Provides Clinical Update
May 28, 2020 7:00am EDT Can-Fite to Host First Quarter 2020 Financial Results & Clinical Update Conference Call on June 1, 2020
May 21, 2020 7:00am EDT Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office
May 18, 2020 7:00am EDT Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liver Fat and Fibrosis
